以Osimertinib治療臺灣EGFR Exon19 Del且無腦轉移之轉移性非小細胞肺癌患者的成本效益分析

Translated title of the contribution: Cost-effectiveness analysis of Osimertinib in patients with non-CNS, EGFR exon 19 Del mutated metastatic NSCLC in Taiwan

鍾宜庭

Research output: Types of ThesisMaster's thesis

Translated title of the contributionCost-effectiveness analysis of Osimertinib in patients with non-CNS, EGFR exon 19 Del mutated metastatic NSCLC in Taiwan
Original languageChinese (Traditional)
Supervisors/Advisors
  • Cheng, Jur-Shan, Supervisor
StatePublished - 2021
Externally publishedYes

Cite this